Found 18 articles for: "biologic"
A Review of the Relationship Between Cutibacterium acnes, Biofilms, and Keratosis Pilaris
June 2026 | Volume 25 | Issue 6 | Features | e53 | Copyright © June 2026
Brodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence
March 2026 | Volume 25 | Issue 3 | Original Article | 211 | Copyright © March 2026
Background: Plaque psoriasis is a chronic immune-mediated disease driven by proinflammatory cytokines. Brodalumab--a recombinant, human monoclonal antibody that functions as an i...
Read MoreReal-World Evidence of Brodalumab Effectiveness for the Treatment of Psoriasis
February 2026 | Volume 25 | Issue 2 | Original Article | 126 | Copyright © February 2026
Brodalumab is a recombinant, fully human monoclonal antibody antagonist of the human interleukin-17 (IL-17) receptor A. It is indicated for the treatment of moderate-to-severe plaque psoriasis in...
Read MoreTreatment of Generalized Granuloma Annulare With Biologics and Oral JAK Inhibitors: A Case Series
February 2026 | Volume 25 | Issue 2 | Features | e26 | Copyright © February 2026
The Role of Simultaneous Janus Kinase Inhibitor and Biologic Therapy Use for Refractory Atopic Dermatitis
October 2025 | Volume 24 | Issue 10 | Case Reports | 1043 | Copyright © October 2025
Two-Year Treatment Persistence of Guselkumab vs Other Biologics in Plaque Psoriasis Patients
August 2025 | Volume 24 | Issue 8 | Original Article | 762 | Copyright © August 2025
Objective: The study objective was to compare long-term treatment persistence between patients initiating guselkumab vs 3 commonly prescribed biologics in the United States.Read MoreThe Use of Biologic Therapeutic Regimens in Cutaneous and Systemic Mastocytosis: A Scoping Review
July 2025 | Volume 24 | Issue 7 | Original Article | 687 | Copyright © July 2025
Background: Mastocytoses, a category of diseases characterized by the clonal proliferation of mast cells and the release of their mediators, can be broadly classified as systemic...
Read MoreGuselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc Analyses
February 2025 | Volume 24 | Issue 2 | Original Article | 196 | Copyright © February 2025
Background: The pivotal Phase 3 VOYAGE 1 and VOYAGE 2 studies established the robust efficacy and safety of guselkumab for up to 5 years in patients with moderate-to-severe psori...
Read MorePersistence With Biologic Treatments in Psoriasis: A Structured Literature Review of Studies Using Administrative Database and Clinical Registry Data
August 2022 | Volume 21 | Issue 8 | Original Article | 881 | Copyright © August 2022
Background: Psoriasis is a chronic, autoimmune-mediated inflammatory disorder. Drug persistence is a composite measure of effectiveness, safety, and treatment satisfaction, often esti...
Read MoreSevere Psoriasis Presenting in 3-Year-Old Child With Nail Dystrophy: Response to Biologic Treatment
August 2022 | Volume 21 | Issue 8 | Case Reports | 897 | Copyright © August 2022
Psoriasis, a chronic inflammatory skin condition, affects about 2% of children. A small subset have isolated nail involvement refractory to topical treatment that can be disabling. The development of ...
Read MoreNew Biologics and Oral Drugs in Treatment of Moderate to Severe Psoriasis
August 2022 | Volume 21 | Issue 8 | Original Article | 826 | Copyright © August 2022
Psoriasis is known to have no definitive cure, which is in common with other inflammatory disorders. Various treatment options are available, and they help in decreasing the disease activity and impro...
Read MoreOnset of Plaque Psoriasis Treatment Responses With Anti-IL-17/IL-23 Biologic Therapies
August 2022 | Volume 21 | Issue 8 | Original Article | 854 | Copyright © August 2022
Background: The impact of psoriasis on quality of life arises from both physical symptoms, such as pain and pruritus, and the psychosocial effects of the often highly visible lesions....
Read MoreA Retrospective Review of Patients’ Response to Biologic Therapy for Psoriasis
April 2021 | Volume 20 | Issue 4 | Original Article | 442 | Copyright © April 2021
Background: Biologic treatments have taken the forefront in treating moderate-to-severe psoria...
Read MoreCOVID-19 Vaccine and Biologics: An Impending Dilemma
January 2021 | Volume 20 | Issue 1 | Editorials | 115 | Copyright © January 2021
The COVID-19 pandemic has forced healthcare providers across all specialties to adjust their methods of clinical practice. I...
Read MoreBiological Effects of Hyaluronic Acid-Based Dermal Fillers and Laser Therapy on Human Skin Models
September 2020 | Volume 19 | Issue 9 | Features | 897 | Copyright © September 2020
Injection of dermal fillers is one of the most frequently performed aesthetic procedures. The aim of the present study was to investigate the biological effects of different stabilized hyaluronan (HA)...
Read MoreBiologics and Small Molecules in the Treatment of COVID-19
June 2020 | Volume 19 | Issue 6 | Features | 673 | Copyright © June 2020
Clinical and Molecular Effects of Interleukin-17 Pathway Blockade in Psoriasis
February 2020 | Volume 19 | Issue 2 | Original Article | 138 | Copyright © February 2020
The interleukin-17 (IL-17) pathway plays a crucial role in the development of psoriasis. Briefly, naive T cells differentiate into helper ...
Read MorePrescribing Patterns Associated With Biologic Therapies for Psoriasis from a United States Medical Records Database
August 2019 | Volume 18 | Issue 8 | Original Article | 745 | Copyright © August 2019
Introduction: Selecting a systemic therapy for patients with psoriasis is a complex process, based on a variety of factors including psoriasis severity, comorbid health conditions, ac...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
